SAN

76.22

-1.49%↓

UCB

260

+0.15%↑

SHL.DE

38.3

+0.05%↑

ARGX

609

-1.58%↓

PHIA

24.37

-0.61%↓

SAN

76.22

-1.49%↓

UCB

260

+0.15%↑

SHL.DE

38.3

+0.05%↑

ARGX

609

-1.58%↓

PHIA

24.37

-0.61%↓

SAN

76.22

-1.49%↓

UCB

260

+0.15%↑

SHL.DE

38.3

+0.05%↑

ARGX

609

-1.58%↓

PHIA

24.37

-0.61%↓

SAN

76.22

-1.49%↓

UCB

260

+0.15%↑

SHL.DE

38.3

+0.05%↑

ARGX

609

-1.58%↓

PHIA

24.37

-0.61%↓

SAN

76.22

-1.49%↓

UCB

260

+0.15%↑

SHL.DE

38.3

+0.05%↑

ARGX

609

-1.58%↓

PHIA

24.37

-0.61%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Avatud

28.6 -2.39

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.55

Max

29.75

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	-21.64% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	1. apr 2026

Turustatistika
By TradingEconomics
Turukapital	1.4B
Eelmine avamishind	30.99
Eelmine sulgemishind	28.6

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. märts 2026, 22:42 UTC

Tulu

Prudential PLC 2025 Adjusted Operating Profit Rises

17. märts 2026, 21:40 UTC

Tulu

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17. märts 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17. märts 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17. märts 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. märts 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17. märts 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17. märts 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17. märts 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17. märts 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17. märts 2026, 22:20 UTC

Tulu

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17. märts 2026, 22:20 UTC

Tulu

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17. märts 2026, 22:07 UTC

Tulu

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17. märts 2026, 22:05 UTC

Tulu

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17. märts 2026, 22:04 UTC

Tulu

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17. märts 2026, 22:03 UTC

Tulu

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17. märts 2026, 21:26 UTC

Tulu

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17. märts 2026, 21:09 UTC

Tulu

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17. märts 2026, 21:08 UTC

Tulu

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17. märts 2026, 21:08 UTC

Tulu

Couche-Tard 3Q Adj EPS 81c >ATD.T

17. märts 2026, 21:07 UTC

Tulu

Couche-Tard 3Q EPS 82c >ATD.T

17. märts 2026, 21:06 UTC

Tulu

Couche-Tard 3Q Rev $21.8B >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Adj EPS 81c >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Rev $21.8B >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q EPS 82c >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Net $757.2M >ATD.T

17. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

-21.64% langus

12 kuu keskmine prognoos

Keskmine 23 EUR -21.64%

Kõrge 23 EUR

Madal 23 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.